ABSTRACT
PURPOSE: Breast cancer incidence increases in the elderly but data on treatment and outcomes of elderly patients is limited. We assessed the clinicopathological features and outcomes of our patients with breast cancer aged ≥80 years in comparison with their younger postmenopausal counterparts. METHODS: The records of 83 patients diagnosed with breast cancer after the age of 80 (group 1) between 2003 and 2011 in 4 different centers were retrospectively evaluated and the clinicopathological features and outcomes were assessed in comparison with a control group (group 2) of 249 patients aged between 60-70 years. RESULTS: Median ages at diagnosis were 82 years (range 80-95) and 64 years (range 60-70) for group 1 and group 2, respectively. The incidence of invasive cancers other than ductal or lobular type was higher in group 1 than in group 2 (20 vs 8%; p=0.0177rpar;. More patients in group 1 had Charlson Comorbidty scores ≥1 than those in group 2 (49 vs 36%; p=0.011). Patients in group 1 had more conservative operations and less axillary node dissections (ALND) and they received chemotherapy, trastuzumab or radiotherapy less frequently compared to their younger counterparts in group 2. Median follow up period was 36 months (range 1-178) in group 1 and 24 months (range 12-217) in group 2. Five-year disease free survival (DFS) was 53.7 and 75.9) (p=0.005), 5-year overall survival (OS) was 61.9% and 80.47percnt; in group 1 and group 2 (p=0.001), respectively. Advanced stage (stage IV vs stage I, II, III, p=0.051) and cerbB2 positivity (p<0.001) were found to be associated with shorter DFS in patients ≥80 years of age. CONCLUSION: Although the majority of patients were undertreated in our study according to the current guidelines, mortality rates were quite low. Different biology of the disease in the elderly might explain this difference.
Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Mastectomy , Age Factors , Aged , Aged, 80 and over , Breast Neoplasms/epidemiology , Chemotherapy, Adjuvant , Chi-Square Distribution , Comorbidity , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymph Node Excision , Mastectomy/adverse effects , Mastectomy/methods , Mastectomy/mortality , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness , Neoplasm Staging , Radiotherapy, Adjuvant , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Turkey/epidemiologySubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Breast Neoplasms/drug therapy , Endometrial Neoplasms/drug therapy , Receptor, ErbB-2/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Cisplatin/administration & dosage , Endometrial Neoplasms/chemistry , Endometrial Neoplasms/pathology , Female , Humans , Treatment OutcomeABSTRACT
We report a case of a 48-year-old woman with a complaint of chronic pelvic pain with a pelvic mass not related with uterus or adnexes. Preoperative ultrasonography or contrast enhanced computed tomography did not give accurate information on the origin of tumor. At laparotomy a cystic, retroperitoneal mass was totally resected without rupture. Final histopathological examination revealed that cystic spaces with abundant lymphocytes suggesting lymphangioma. No recurrence was detected in the follow up 6 months after total resection. As a result cystic lymphangioma should be considered as a rare cause of pelvic mass in women.
Subject(s)
Lymphangioma, Cystic/complications , Pelvic Neoplasms/complications , Pelvic Pain/etiology , Retroperitoneal Neoplasms/complications , Adult , Female , Histocytochemistry , Humans , Laparotomy , Lymphangioma, Cystic/diagnostic imaging , Pelvic Neoplasms/diagnostic imaging , Radiography , Retroperitoneal Neoplasms/diagnostic imaging , UltrasonographySubject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents/administration & dosage , Carboplatin/administration & dosage , Carcinoma/drug therapy , Carcinoma/surgery , Fallopian Tube Neoplasms/drug therapy , Paclitaxel/administration & dosage , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma/pathology , Fallopian Tube Neoplasms/pathology , Fallopian Tube Neoplasms/surgery , Female , Humans , Middle Aged , Neoplasm Staging , Second-Look SurgerySubject(s)
Amenorrhea , Breast Neoplasms/mortality , Obesity/complications , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Body Mass Index , Breast Neoplasms/drug therapy , Breast Neoplasms/therapy , Female , Humans , Middle Aged , Premenopause , Prognosis , Survival Analysis , Treatment OutcomeSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Head and Neck Neoplasms/therapy , Cisplatin/administration & dosage , Combined Modality Therapy , Cyclooxygenase Inhibitors/administration & dosage , Head and Neck Neoplasms/radiotherapy , Humans , Randomized Controlled Trials as Topic , Treatment OutcomeABSTRACT
Palmoplantar keratoderma (PPK) is a congenital or acquired disorder characterized by the abnormal thickening of the skin of the palms and soles. The thickening can present as a diffuse, focal or punctate pattern. It has been reported to be associated with internal malignancies such as lung and esophageal carcinomas. When PPK is associated with malignancy the prognosis is poor. Patients with these conditions should undergo frequent medical examinations, which should include chest radiography and cytologic examination of the sputum. The present patient is a 47-year-old-man with PPK who suffered from metastatic non-small-cell carcinoma of the lung.
Subject(s)
Carcinoma, Non-Small-Cell Lung/complications , Keratoderma, Palmoplantar, Diffuse/etiology , Lung Neoplasms/complications , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/therapy , Foot/pathology , Hand/pathology , Humans , Keratoderma, Palmoplantar, Diffuse/pathology , Keratoderma, Palmoplantar, Diffuse/therapy , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Male , Middle Aged , Prognosis , Skin/pathologyABSTRACT
The differential diagnosis of eosinophilia may sometimes be difficult. Eosinophilia may occur in a diverse array of conditions from parasitic infestations to malignacies. Idiopathic hypereosinophilic syndrome has also been described. A 65-year-old male patient presenting with eosinophilia of obscure etiology is described in the present report. Three years after the diagnosis of eosinophilia, metastatic anaplastic carcinoma of unknown primary was detected. Differential diagnosis is disscussed briefly. It is stressed that patients with hypereosinophilia of unknown etiology must be screened for malignancy regularly during follow up.
Subject(s)
Abdominal Neoplasms/diagnosis , Carcinoma/diagnosis , Hypereosinophilic Syndrome/diagnosis , Hypereosinophilic Syndrome/etiology , Neoplasms, Unknown Primary/diagnosis , Abdominal Neoplasms/pathology , Aged , Bone Marrow/pathology , Carcinoma/pathology , Diagnosis, Differential , Fatal Outcome , Humans , Hypereosinophilic Syndrome/pathology , Liver Neoplasms/diagnosis , Lung Neoplasms/diagnosis , Male , Neoplasms, Unknown Primary/pathologyABSTRACT
PURPOSE: This study was performed to evaluate relations among neutrophil count (including its course), type of lesion, treatment, and prognosis in patients with leukemia and perianal infection. METHODS: Medical records of patients with acute and chronic leukemia who were followed during the last five years were reviewed retrospectively. RESULTS: The incidence of perianal infections was found to be 7.3 percent in 259 patients with acute leukemia. Only 1 of 108 patients with chronic leukemia suffered from this problem. Twenty percent of all patients with this complication died as a result of sepsis. Perianal abscess was the sole and obligatory indication for surgical treatment in our patients. There were ten patients in each treatment group. The operative group had better results (9 cures, 1 complication vs. 3 cures, 7 complications). However, median neutrophil count at diagnosis was notably higher in the operative group 1,280/mm3 vs. 96/mm3; P = 0.075). Also, significantly more frequent abscess formations and, consequently, operative treatments were performed in patients with a period of normal neutrophil counts during the infection compared with continuously neutropenic patients (9 operative, 4 nonoperative vs. 1 operative, 6 nonoperative; P = 0.057). Ten cures, three complications vs. two cures, five complications (3 mortalities) were present in patients with and without normal neutrophil counts, respectively (P = 0.062). When only severely neutropenic patients were considered, four patients in the surgery group had normal neutrophil counts before or shortly after surgery. However, only two of eight patients with perianal cellulitis had normal counts during full-course infection (P = 0.06). CONCLUSIONS: The course of the neutrophil count during infection was an important factor affecting the perianal lesion, and indirectly, choice of treatment and prognosis. A period of normal counts during infection usually led to well bordered and fluctuant lesions, and the prognosis was acceptable with operative treatment. However, continuously neutropenic patients developed nonfluctuating indurations. We found disappointing results with nonoperative treatment of such patients. In all studies, regarding treatment of perianal infections in neutropenic patients, the course of the neutrophil count and indications for surgery should be clarified to get reliable results.